Tevogen provides update on TVGN 489 amid Long COVID patient interest

Tevogen (TVGN) issued an update regarding growing public interest in its investigational precision T cell therapy, TVGN 489, under development for COVID-19 and Long COVID. “We’re deeply moved by the number of Long COVID patients expressing interest in TVGN 489,” said Ryan Saadi, CEO of Tevogen Bio. “This level of engagement underscores the urgent need for effective and durable solutions. Our team remains fully committed to advancing this science with both urgency and care.” The company’s dose-finding clinical trial of TVGN 489 demonstrated a favorable safety profile and provided insights for the next phase of development. The results were peer-reviewed and published in Blood Advances, the journal of the American Society of Hematology. While TVGN 489 is not yet available for broader clinical use, Tevogen is actively preparing for the next stage of development. The company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development and maximize patient access once regulatory pathways allow.